Search

Your search keyword '"Valenzuela, Claudia"' showing total 547 results
Start Over Author "Valenzuela, Claudia"
547 results on '"Valenzuela, Claudia"'

2. Chromosomal instability in a patient with ring chromosome 14 syndrome: a case report

Author

Meza-Espinoza, Juan Pablo, González-García, Juan Ramón, Nieto-Marín, Nayeli, Patrón-Baro, Liliana Itzel, González-Arreola, Rosa María, Arámbula-Meraz, Eliakym, Benítez-Pascual, Julio, De la Herrán-Arita, Alberto Kousuke, Norzagaray-Valenzuela, Claudia Desireé, Valdez-Flores, Marco Antonio, Carrillo-Cázares, Tomás Adrián, and Picos-Cárdenas, Verónica Judith

Published
2024
Full Text
View/download PDF

3. Association between lipid profile and clinical outcomes in COVID-19 patients

Author

Ochoa-Ramírez, Luis Antonio, De la Herrán Arita, Alberto Kousuke, Sanchez-Zazueta, Jorge Guillermo, Ríos-Burgueño, Efrén, Murillo-Llanes, Joel, De Jesús-González, Luis Adrián, Farfan-Morales, Carlos Noe, Cordero-Rivera, Carlos Daniel, del Ángel, Rosa María, Romero-Utrilla, Alejandra, Camberos-Barraza, Josué, Valdez-Flores, Marco Antonio, Camacho-Zamora, Alejandro, Batiz-Beltrán, José Candelario, Angulo-Rojo, Carla, Guadrón-Llanos, Alma Marlene, Picos-Cárdenas, Verónica Judith, Norzagaray-Valenzuela, Claudia Desiree, Rábago-Monzón, Ángel Radamés, Velarde-Félix, Jesús Salvador, Reyes-Ruiz, José Manuel, and Osuna-Ramos, Juan Fidel

Published
2024
Full Text
View/download PDF

5. Births: Final Data for 2022

Author

Osterman, Michelle, primary, Hamilton, Brady, additional, Martin, Joyce, additional, Driscoll, Anne, additional, and Valenzuela, Claudia, additional

Published
2024
Full Text
View/download PDF

6. Influencia de las guías de práctica clínica en el diagnóstico y tratamiento de la fibrosis pulmonar idiopática. Datos del Registro de la Sociedad Española de Neumología y Cirugía Torácica

Author

Aburto, Myriam, Rodríguez-Portal, José Antonio, Fernandez-Fabrellas, Estrella, García Sevila, Raquel, Herrera Lara, Susana, Bollo de Miguel, Elena, González Ruiz, José María, Molina-Molina, María, Safont Muñoz, Belén, Godoy Mayoral, Raul, Romero Ortiz, Ana Dolores, Soler Sempere, María José, Castillo Villegas, Diego, Gaudó Navarro, Javier, Tomás López, Laura, Nuñez Sanchez, Belén, Palacios Hidalgo, Zulema, Sellares Torres, Jacobo, Sacristán Bou, Lirios, Nieto Barbero, María Asunción, Casanova Espinosa, Alvaro, Portillo-Carroz, Karina, Cano-Jimenez, Esteban, Acosta Fernández, Orlando, Legarreta, María José, and Valenzuela, Claudia

Published
2024
Full Text
View/download PDF

11. Scientific facts improve cannabis perception and public opinion: results from Sinaloa, México

Author

Camberos-Barraza, Josué, Osuna-Ramos, Juan F., Rábago-Monzón, Ángel R., Quiñonez-Angulo, Luis F., González-Peña, Héctor R., Pérez-Ramos, Alan A., Camacho-Zamora, Alejandro, López-Lazcano, Héctor, Valdez-Flores, Marco A., Angulo-Rojo, Carla E., Guadrón-Llanos, Alma M., Picos-Cárdenas, Verónica J., Norzagaray-Valenzuela, Claudia D., and De la Herrán-Arita, Alberto K.

Published
2023
Full Text
View/download PDF

12. Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World.

Author

Polke, Markus, Kondoh, Yasuhiro, Wijsenbeek, Marlies, Cottin, Vincent, Walsh, Simon, Collard, Harold, Chaudhuri, Nazia, Avdeev, Sergey, Behr, Jürgen, Calligaro, Gregory, Corte, Tamera, Flaherty, Kevin, Funke-Chambour, Manuela, Kolb, Martin, Krisam, Johannes, Maher, Toby, Molina Molina, Maria, Morais, Antonio, Moor, Catharina, Morisset, Julie, Pereira, Carlos, Quadrelli, Silvia, Selman, Moises, Tzouvelekis, Argyrios, Valenzuela, Claudia, Vancheri, Carlo, Vicens-Zygmunt, Vanesa, Wälscher, Julia, Wuyts, Wim, Bendstrup, Elisabeth, and Kreuter, Michael

Subjects
acute exacerbation, idiopathic pulmonary fibrosis, non-specialised ILD centres, pulmonologists, questionnaire, specialised ILD centres
Abstract

Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication associated with a high mortality. However, evidence and guidance on management is sparse. The aim of this international survey was to assess differences in prevention, diagnostic and treatment strategies for AE-IPF in specialised and non-specialised ILD centres worldwide. Material and Methods: Pulmonologists working in specialised and non-specialised ILD centres were invited to participate in a survey designed by an international expert panel. Responses were evaluated in respect to the physicians institutions. Results: Three hundred and two (65%) of the respondents worked in a specialised ILD centre, 134 (29%) in a non-specialised pulmonology centre. Similarities were frequent with regards to diagnostic methods including radiology and screening for infection, treatment with corticosteroids, use of high-flow oxygen and non-invasive ventilation in critical ill patients and palliative strategies. However, differences were significant in terms of the use of KL-6 and pathogen testing in urine, treatments with cyclosporine and recombinant thrombomodulin, extracorporeal membrane oxygenation in critical ill patients as well as antacid medication and anaesthesia measures as preventive methods. Conclusion: Despite the absence of recommendations, approaches to the prevention, diagnosis and treatment of AE-IPF are comparable in specialised and non-specialised ILD centres, yet certain differences in the managements of AE-IPF exist. Clinical trials and guidelines are needed to improve patient care and prognosis in AE-IPF.

Published
2021

13. Variability in Global Prevalence of Interstitial Lung Disease

Author

Kaul, Bhavika, Cottin, Vincent, Collard, Harold R, and Valenzuela, Claudia

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Sciences, Lung, Clinical Research, 2.4 Surveillance and distribution, Aetiology, Respiratory, interstitial lung disease, epidemiology-descriptive, global epidemiology, idiopathic pulmonary fibrosis, mortality, epidemiology—descriptive, Biomedical and clinical sciences, Health sciences
Abstract

There are limited epidemiologic studies describing the global burden and geographic heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen methodologically heterogenous studies that examined the incidence, prevalence and relative frequencies of ILDs, the incidence of ILD ranged from 1 to 31.5 per 100,000 person-years and prevalence ranged from 6.3 to 71 per 100,000 people. In North America and Europe, idiopathic pulmonary fibrosis and sarcoidosis were the most prevalent ILDs while the relative frequency of hypersensitivity pneumonitis was higher in Asia, particularly in India (10.7-47.3%) and Pakistan (12.6%). The relative frequency of connective tissue disease ILD demonstrated the greatest geographic variability, ranging from 7.5% of cases in Belgium to 33.3% of cases in Canada and 34.8% of cases in Saudi Arabia. These differences may represent true differences based on underlying characteristics of the source populations or methodological differences in disease classification and patient recruitment (registry vs. population-based cohorts). There are three areas where we feel addition work is needed to better understand the global burden of ILD. First, a standard ontology with diagnostic confidence thresholds for comparative epidemiology studies of ILD is needed. Second, more globally representative data should be published in English language journals as current literature has largely focused on Europe and North America with little data from South America, Africa and Asia. Third, the inclusion of community-based cohorts that leverage the strength of large databases can help better estimate population burden of disease. These large, community-based longitudinal cohorts would also allow for tracking of global trends and be a valuable resource for collective study. We believe the ILD research community should organize to define a shared ontology for disease classification and commit to conducting global claims and electronic health record based epidemiologic studies in a standardized fashion. Aggregating and sharing this type of data would provide a unique opportunity for international collaboration as our understanding of ILD continues to grow and evolve. Better understanding the geographic and temporal patterns of disease prevalence and identifying clusters of ILD subtypes will facilitate improved understanding of emerging risk factors and help identify targets for future intervention.

Published
2021

15. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology

Author

Narváez, Javier, Aburto, Myriam, Seoane-Mato, Daniel, Bonilla, Gema, Acosta, Orlando, Candelas, Gloria, Cano-Jiménez, Esteban, Castellví, Iván, González-Ruiz, José María, Corominas, Héctor, López-Muñiz, Belén, Martín-López, María, Robles-Pérez, Alejandro, Mena-Vázquez, Natalia, Rodríguez-Portal, José Antonio, Ortiz, Ana María, Sabater-Abad, Cristina, Castrejón, Isabel, dos Santos, Raquel, Garrote-Corral, Sandra, Maese, Jesús, Silva-Fernández, Lucía, Castañeda, Santos, and Valenzuela, Claudia

Published
2023
Full Text
View/download PDF

16. Criterios de cribado de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide: propuesta de expertos basada en metodología Delphi

Author

Narváez, Javier, Aburto, Myriam, Seoane-Mato, Daniel, Bonilla, Gema, Acosta, Orlando, Candelas, Gloria, Cano-Jiménez, Esteban, Castellví, Iván, González-Ruiz, José María, Corominas, Héctor, López-Muñiz, Belén, Martín-López, María, Robles-Pérez, Alejandro, Mena-Vázquez, Natalia, Rodríguez-Portal, José Antonio, Ortiz, Ana María, Sabater-Abad, Cristina, Castrejón, Isabel, dos Santos, Raquel, Garrote-Corral, Sandra, Maese, Jesús, Silva-Fernández, Lucía, Castañeda, Santos, and Valenzuela, Claudia

Published
2023
Full Text
View/download PDF

21. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

Author

Narváez, Javier, Díaz del Campo Fontecha, Petra, Brito García, Noé, Bonilla, Gema, Aburto, Myriam, Castellví, Iván, Cano-Jiménez, Esteban, Mena-Vázquez, Natalia, Nieto, M. Asunción, Ortiz, Ana María, Valenzuela, Claudia, Abad Hernández, Miguel Ángel, Castrejón, Isabel, Correyero Plaza, María, Francisco Hernández, Félix Manuel, Hernández Hernández, María Vanesa, and Rodríquez Portal, José Antonio

Published
2022
Full Text
View/download PDF

22. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento

Author

Narváez, Javier, Díaz del Campo Fontecha, Petra, Brito García, Noé, Bonilla, Gema, Aburto, Myriam, Castellví, Iván, Cano-Jiménez, Esteban, Mena-Vázquez, Natalia, Nieto, M. Asunción, Ortiz, Ana María, Valenzuela, Claudia, Abad Hernández, Miguel Ángel, Castrejón, Isabel, Correyero Plaza, María, Francisco Hernández, Félix Manuel, Hernández Hernández, María Vanesa, and Rodríquez Portal, José Antonio

Published
2022
Full Text
View/download PDF

23. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis

Author

Rodríguez Portal, José Antonio, Brito García, Noé, Díaz del Campo Fontecha, Petra, Valenzuela, Claudia, Ortiz, Ana María, Nieto, M. Asunción, Mena-Vázquez, Natalia, Cano-Jiménez, Esteban, Castellví, Iván, Aburto, Myriam, Bonilla, Gema, Hernández Hernández, María Vanesa, Francisco Hernández, Félix Manuel, Correyero Plaza, María, Castrejón, Isabel, Abad Hernández, Miguel Ángel, and Narváez, Javier

Published
2022
Full Text
View/download PDF

24. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico

Author

Rodríguez Portal, José Antonio, Brito García, Noé, Díaz del Campo Fontecha, Petra, Valenzuela, Claudia, Ortiz, Ana María, Nieto, M. Asunción, Mena-Vázquez, Natalia, Cano-Jiménez, Esteban, Castellví, Iván, Aburto, Myriam, Bonilla, Gema, Hernández Hernández, María Vanesa, Hernández, Félix Manuel Francisco, Correyero Plaza, María, Castrejón, Isabel, Abad Hernández, Miguel Ángel, and Narváez, Javier

Published
2022
Full Text
View/download PDF

27. Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study.

Author

Lancaster, Lisa, Cottin, Vincent, Ramaswamy, Murali, Wuyts, Wim A., Jenkins, R. Gisli, Scholand, Mary Beth, Kreuter, Michael, Valenzuela, Claudia, Ryerson, Christopher J., Goldin, Jonathan, Kim, Grace Hyun J., Jurek, Marzena, Decaris, Martin, Clark, Annie, Turner, Scott M., Barnes, Chris N., Achneck, Hardean E., Cosgrove, Gregory P., Lefebvre, Éric A., and Flaherty, Kevin R.

Subjects
IDIOPATHIC pulmonary fibrosis, CRITICAL care medicine, LUNG diseases, DISEASE progression, PLACEBOS
Abstract

What is this summary about? This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of Respiratory and Critical Care Medicine in 2024. This study looked at a medicine called bexotegrast (beck-so-teh-grast) as a possible treatment for idiopathic pulmonary fibrosis (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). Bexotegrast is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment. IPF is a chronic, progressive lung disease that makes it hard to breathe and gets worse over time. There is no cure for IPF, treatment includes symptom management and consideration for the use of nintedanib or pirfenidone, which may decrease the pace of disease progression. The study compared bexotegrast to a placebo (a treatment that looks identical to the medicine but has no medicinal effect) to look at how well it works and how safe it is in treating people with IPF. Most people in the study also took one of two medicines that are already approved by the FDA for IPF, pirfenidone or nintedanib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

Author

Bermudo, Guadalupe, Suarez-Cuartin, Guillermo, Rivera-Ortega, Pilar, Rodriguez-Portal, Jose Antonio, Sauleda, Jaume, Nuñez, Belen, Castillo, Diego, Aburto, Myriam, Portillo, Karina, Balcells, Eva, Badenes-Bonet, Diana, Valenzuela, Claudia, Fernandez-Fabrellas, Estrella, González-Budiño, Teresa, Cano, Esteban, Acosta, Orlando, Leiro-Fernández, Virginia, Romero, Ana, Planas-Cerezales, Lurdes, Villar, Ana, Moreno, Amalia, Laporta, Rosalia, Vicens-Zygmunt, Vanesa, Shull, Jessica, Franquet, Tomàs, Luburich, Patricio, and Molina-Molina, Maria

Published
2022
Full Text
View/download PDF

34. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Study

Author

Lancaster, Lisa, primary, Cottin, Vincent, additional, Ramaswamy, Murali, additional, Wuyts, Wim A., additional, Jenkins, R. Gisli, additional, Scholand, Mary Beth, additional, Kreuter, Michael, additional, Valenzuela, Claudia, additional, Ryerson, Christopher J, additional, Goldin, Jonathan, additional, Kim, Grace Hyun J, additional, Jurek, Marzena, additional, Decaris, Martin, additional, Clark, Annie, additional, Turner, Scott, additional, Barnes, Chris N., additional, Achneck, Hardean E, additional, Cosgrove, Gregory, additional, Lefebvre, Éric A, additional, and Flaherty, Kevin R., additional

Published
2024
Full Text
View/download PDF

36. Births: Final Data for 2021

Author

J.K., Michelle, primary, Hamilton E., Brady, additional, A., Joyce, additional, Driscoll, Anne, additional, and Valenzuela, Claudia, additional

Published
2023
Full Text
View/download PDF

39. Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias

Author

Villar-Álvarez, Felipe, Martínez-García, Miguel Ángel, Jiménez, David, Fariñas-Guerrero, Fernando, Ortiz de Lejarazu-Leonardo, Raúl, López-Campos, José Luis, Blanco-Aparicio, Marina, Royo-Crespo, Íñigo, García-Ortega, Alberto, Trilla-García, Antoni, Trujillo-Reyes, Juan Carlos, Fernández-Prada, María, Díaz-Pérez, David, Laporta-Hernández, Rosalía, Valenzuela, Claudia, Menéndez, Rosario, and de la Rosa-Carrillo, David

Published
2021
Full Text
View/download PDF

42. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.

Author

Lancaster, Lisa, Cottin, Vincent, Ramaswamy, Murali, Wuyts, Wim A., Jenkins, R. Gisli, Scholand, Mary Beth, Kreuter, Michael, Valenzuela, Claudia, Ryerson, Christopher J., Goldin, Jonathan, Kim, Grace Hyun J., Jurek, Marzena, Decaris, Martin, Clark, Annie, Turner, Scott, Barnes, Chris N., Achneck, Hardean E., Cosgrove, Gregory P., Lefebvre, Éric A., and Flaherty, Kevin R.

Subjects
IDIOPATHIC pulmonary fibrosis, COUGH, CLINICAL trials, PULMONARY fibrosis, INVESTIGATIONAL drugs, DRUG development
Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with (NCT04396756). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Antiviral Effect of Microalgae Phaeodactylum tricornutum Protein Hydrolysates against Dengue Virus Serotype 2.

Author

Rivera-Serrano, Bianca Vianey, Cabanillas-Salcido, Sandy Lucero, Cordero-Rivera, Carlos Daniel, Jiménez-Camacho, Ricardo, Norzagaray-Valenzuela, Claudia Desiree, Calderón-Zamora, Loranda, De Jesús-González, Luis Adrián, Reyes-Ruiz, José Manuel, Farfan-Morales, Carlos Noe, Romero-Utrilla, Alejandra, Ruíz-Ruelas, Víctor Manuel, Camberos-Barraza, Josué, Camacho-Zamora, Alejandro, De la Herrán-Arita, Alberto Kousuke, Angulo-Rojo, Carla, Guadrón-Llanos, Alma Marlene, Rábago-Monzón, Ángel Radamés, Perales-Sánchez, Janitzio Xiomara Korina, Valdez-Flores, Marco Antonio, and Del Ángel, Rosa María

Abstract

Dengue, caused by the dengue virus (DENV), is a global health threat transmitted by Aedes mosquitoes, resulting in 400 million cases annually. The disease ranges from mild to severe, with potential progression to hemorrhagic dengue. Current research is focused on natural antivirals due to challenges in vector control. This study evaluates the antiviral potential of peptides derived from the microalgae Phaeodactylum tricornutum, known for its bioactive compounds. Microalgae were cultivated under controlled conditions, followed by protein extraction and hydrolysis to produce four peptide fractions. These fractions were assessed for cytotoxicity via the MTT assay and antiviral activity against DENV serotype 2 using flow cytometry and plaque formation assays. The 10–30 kDa peptide fraction, at 150 and 300 μg/mL concentrations, demonstrated no cytotoxicity and significantly reduced the percentage of infected cells and viral titers. These findings suggest that peptides derived from Phaeodactylum tricornutum exhibit promising antiviral activity against dengue virus serotype 2, potentially contributing to developing new therapeutic approaches for dengue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results